Tag: DLBCL

The Accept Phase Ib/II Single Arm Study

Oral and Poster Abstracts 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III Research, clinical trials, Lymphomas, Clinical Research, Combination therapy, Diseases, aggressive lymphoma, Therapies, Lymphoid Malignancies Andrew J Davies, BSc, BM, FRCP, PhD1,2*, Josh Caddy, BSc3*, Katy McLaughlin, BSc3*, Christopher Wignall, MSc3*, Robert…

Continue Reading The Accept Phase Ib/II Single Arm Study

Incorporating molecular markers in standard prognostic models for DLBCL patients using real-world data.

Remember all your deadlines for grant applications and conference abstracts! Add your email to join our free beta test: Stage (stratigraphy) Hazard ratio Population e19251 Background: NCCN-IPI is a prognostic scoring system that outperforms other risk classification mechanisms in diffuse large B-cell lymphoma (DLBCL) but does not consider the molecular…

Continue Reading Incorporating molecular markers in standard prognostic models for DLBCL patients using real-world data.

Interim 18F-FDG PET validated and included in guidelines for DLBCL

Coreline Burggraaff received her PhD on September 9 at VU University Amsterdam his thesis entitled ‘18F-FDG PET as a biomarker in aggressive lymphoma; technical and clinical validation’. Prof. Dr. JM Zijlstra-Baalbergen and Prof. Dr. Ir. HCW de Vet acted as supervisors. Co-promoters were Prof. Dr. OS Hoekstra and Prof. Dr….

Continue Reading Interim 18F-FDG PET validated and included in guidelines for DLBCL

Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line. New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in addition to chimeric antigen receptor (CAR) T-cell therapy,…

Continue Reading Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

Applications for Epcoritamab Submitted to FDA and EMA in Relapsed/Refractory LBCL/DLBCL

Patients with relapsed/refractory large B-cell lymphoma may benefit from epcoritamab, the biologics license applications of which were submitted to the FDA. A biologics license application for subcutaneous epcoritamab (DuoBody-CD3xCD20) was submitted to the FDA for patients with relapsed/refractory large B-cell lymphoma (LBCL) following 2 or more lines of systemic therapy…

Continue Reading Applications for Epcoritamab Submitted to FDA and EMA in Relapsed/Refractory LBCL/DLBCL

Lessons From ZUMA-7, BELINDA, and TRANSFORM

Dr. Brad Kahl Key Points: Historically, patients with diffuse large B-cell lymphoma (DLBCL) for whom frontline and salvage chemotherapy had failed had little chance of cure; now, 3 chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—show promising prolonged disease-free survival. The ZUMA-7, BELINDA, and TRANSFORM trials compared…

Continue Reading Lessons From ZUMA-7, BELINDA, and TRANSFORM

Transformation of FL into DLBCL with a PMBL gene expression signature | Blood Advances

We investigated the clinicopathologic features of 5 follicular lymphomas (FL) that transformed to morphologic diffuse large B-cell lymphomas (DLBCL) and had a primary mediastinal large B-cell lymphoma (PMBL)-like gene expression profile (tFL-PMBLsig-pos). None of the tFL-PMBLsig-pos arose in the mediastinum, all cases tested had a germinal center B-cell phenotype, 20%…

Continue Reading Transformation of FL into DLBCL with a PMBL gene expression signature | Blood Advances

Tafasitamab Plus Lenalidomide Improve Outcomes Vs Systemic Therapies in Relapsed/Refractory DLBCL

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) experienced prolonged overall survival (OS) following treatment with tafasitamab (Monjuvi) and lenalidomide (Revlimid), meeting the primary end point of the observational retrospective RE-MIND2 cohort study (NCT04697160). Investigators compared tafasitamab and lenalidomide vs pooled systemic therapies; bendamustine/rituximab (Rituxan); and rituximab plus gemcitabine and…

Continue Reading Tafasitamab Plus Lenalidomide Improve Outcomes Vs Systemic Therapies in Relapsed/Refractory DLBCL

Tafasitamab/Lenalidomide Shows Efficacy for 2+ Years in R/R DLBCL

Updated results from the L-MIND trial show continued efficacy and safety data for the combination of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma. Tafasitamab-cxix (Monjuvi) plus lenalidomide (Revlimid) showed long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who were treated for at…

Continue Reading Tafasitamab/Lenalidomide Shows Efficacy for 2+ Years in R/R DLBCL

Electrochemistry Analysis of Drugs Summarized in Lenvatinibdextrins

Therefore, these systems generally have to have a advanced level involving computational sources as well as run-time, which usually boosts as the difficulty along with the size the information sets. It is known that computational charges are mainly due to continuing assessment technique of the guidelines and also the men…

Continue Reading Electrochemistry Analysis of Drugs Summarized in Lenvatinibdextrins

Lymphoma, 2 out of 3 Italians know it but only 20% know the symptoms

There are over 150 thousand people affected by non-Hodgkin’s lymphoma in Italy. Two out of 3 Italians declare that they know lymphomas, 3% have had direct experience of them, but they have limited and superficial knowledge: only 20% recognize at least 3 symptoms. Diffuse large B-cell lymphoma (Dlbcl) is the…

Continue Reading Lymphoma, 2 out of 3 Italians know it but only 20% know the symptoms

Clinical Significance of MYD88 non-L265P Mutations in Diffuse Large B-Cell Lymphoma

doi: 10.1002/hon.3073. Online ahead of print. Affiliations Expand Affiliations 1 Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong…

Continue Reading Clinical Significance of MYD88 non-L265P Mutations in Diffuse Large B-Cell Lymphoma

Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations

Joseph E Maakaron, assistant professor of medicine, Marie Hu, assistant professor of medicine, Najla El Jurdi, assistant professor of medicine University of Minnesota Twin Cities, Minneapolis, United States Correspondence to: maaka001{at}umn.edu Abstract Chimeric antigen receptor T cells have revolutionized the treatment of hematological malignancies during the past five years, boasting…

Continue Reading Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations

CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS IN PRIMARY BREAST DIFFUSE LARGE B-CELL LYMPHOMA

Keywords Diffuse large B-cell lymphoma, Breast, Prognostic factors, Relapse, Central nervous system References [1] C. Wiseman, and K.T. Liao, Primary lymphoma of the breast. Cancer 29 (1972) 1705-12.www.ncbi.nlm.nih.gov/pubmed/4555557 [2] P.J. Hosein, J.C. Maragulia, M.P. Salzberg, O.W. Press, T.M. Habermann, J.M. Vose, M. Bast, R.H. Advani, R. Tibshirani, A.M. Evens, N….

Continue Reading CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS IN PRIMARY BREAST DIFFUSE LARGE B-CELL LYMPHOMA

InnoCare Releases 2022 Mid-Year Results and Business Highlights

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2022 mid-year results which ended on June 30, 2022. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare said: “The announcement of 2022 mid-year results coincides with our seventh anniversary. In the challenging…

Continue Reading InnoCare Releases 2022 Mid-Year Results and Business Highlights

Genentech DLBCL treatment gets FDA approval

Genentech, a part of the Roche Group, says the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Polivy. Polivy (polatuzumab vedotin-piiq), in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large…

Continue Reading Genentech DLBCL treatment gets FDA approval

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma | Molecular Medicine

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. CAS  PubMed  Article  Google Scholar  Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large…

Continue Reading Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma | Molecular Medicine

US approves BMS CAR-T in large B-cell lymphoma

Samit Hirawat, medical director of Bristol Myers Squibb. Bristol Myers Squibb has announced that the US Drug Evaluation Agency (FDA) has approved Breyanzi (lisocabtagene maraleucel; lisa-cel), a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with large B-cell lymphoma (DLB), including diffuse large B-cell lymphoma…

Continue Reading US approves BMS CAR-T in large B-cell lymphoma

ASCT is no longer suitable for the majority of patients with DLBCL

Most patients with diffuse large B-cell lymphoma (DLBCL) do not experience significant benefit from treatment with autologous stem cell transplantation (ASCT) and better treatment options are currently available for this population, according to a presentation at the Pan Pacific Lymphoma Conference 2022.1 “ASCT is lousy therapy in the modern age,”…

Continue Reading ASCT is no longer suitable for the majority of patients with DLBCL

Dog lymphoma, new genetic mutations discovered. Hopes for man too

TURIN – Large B cell lymphoma is one of the most frequent cancers in dogs and is considered a good model for the study of the same pathology in humans. The study was published in the prestigious Nature journal, Lab Animal. Researchers of a European team coordinated by the professor…

Continue Reading Dog lymphoma, new genetic mutations discovered. Hopes for man too

Novartis announces promising five-year data for leukaemia treatment Kymriah

Novartis has shared long-term, five-year follow-up results from its pivotal clinical phase 2 trial, ELIANA, evaluating Kymriah (tisagenlecleucel), the first-ever approved CAR T-cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL). Kymriah is a one-off treatment designed to help patients’ immune…

Continue Reading Novartis announces promising five-year data for leukaemia treatment Kymriah

Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting

BEIJING–(BUSINESS WIRE)–Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Poster Presentation 1: Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer (HNC) harboring FGF/FGFR gene aberrations Abstract…

Continue Reading Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting

bbT369 for Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trial 2022

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team. Is bbt369 typically used in combination with any other treatments? As Bbt369 alone demonstrated significant activity in vitro and in vivo, this drug was usually combined with other agents in…

Continue Reading bbT369 for Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trial 2022

Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL – May 26, 2022

Roche (RHHBY Quick QuoteRHHBY – Free Report) recently announced that the European Commission (“EC”) has granted approval to lymphoma drug Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Polivy is…

Continue Reading Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL – May 26, 2022

CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this report. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of…

Continue Reading CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

DataSheet1_Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.docx

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin’s lymphoma (NHL) with highly heterogeneous genetic and phenotypic features. Therefore, a comprehensive understanding of cellular diversity and intratumoral heterogeneity is essential to elucidate the mechanisms driving DLBCL progression and to develop new therapeutic approaches. Methods: We…

Continue Reading DataSheet1_Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.docx

Clinicopathologic Profile and Treatment Outcomes of Children With Diffuse Large B-cell Lymphomas (DLBCL): Experience From a Tertiary Cancer Center in India

Radnyi Mande, Nirmalya Roy Moulik, Tanuja Shet, Gaurav Narula, Maya Prasad, Chetan Dhamne, Vasudeva Bhat, Badira Cheriyalinkal Parambil, Sneha Shah, Epari Shridhar, Sumeet Gujral, Shripad Banavali Journal of Pediatric Hematology/oncology 2022 February 4 35129150 Clinicopathologic profile and outcome of 15 children (15 years or above) with diffuse large B-cell lymphoma…

Continue Reading Clinicopathologic Profile and Treatment Outcomes of Children With Diffuse Large B-cell Lymphomas (DLBCL): Experience From a Tertiary Cancer Center in India

Primary Extra Nodal Diffuse Large B-Cell Lymphoma of the Maxillary Sinus with Symptoms of Acute Pulpitis

Case Reports . 2022 Apr 7;2022:8875832. doi: 10.1155/2022/8875832. eCollection 2022. Affiliations Expand Affiliation 1 Department of Stomatology, The First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China. Item in Clipboard Case Reports Jian-Tong Cui et al. Case Rep Dent. 2022. Show details Display options Display options Format AbstractPubMedPMID . 2022…

Continue Reading Primary Extra Nodal Diffuse Large B-Cell Lymphoma of the Maxillary Sinus with Symptoms of Acute Pulpitis

Diffuse Large B-Cell Lymphoma: Causes, Symptoms, Treatment

Diffuse large B-cell lymphoma (DLBCL) is a cancer of the B cells of the lymphatic system. B cells are responsible for producing antibodies, which are highly specific proteins that fight against bacterial and viral infections. When cancer develops in the B cells, it is called a B-cell lymphoma. B-cell lymphoma…

Continue Reading Diffuse Large B-Cell Lymphoma: Causes, Symptoms, Treatment

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial

Covalent menin inhibitor BMF-219 showed strong cytotoxic activity as a single agent at similar concentrations across multiple preclinical patient derived (PDX) models ex vivo, including diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer Single agent BMF-219 demonstrated pronounced anti-cancer activity…

Continue Reading Biomea Fusion Reports Preclinical Data on BMF-219 and Trial

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL

Key messages What is already known on this topic Targeting immunosuppressive pathways have emerged as promising strategies for cancer treatment. The genetic characteristics of PD-1/PD-L1/L2 (programmed cell death protein 1/programmed cell death ligand 1/ligand 2) and CD73/A2aR (A2a adenosine receptor) and the effect of these two signalings on dysfunctional CD8+…

Continue Reading Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL

Polatuzumab Vedotin Plus R-CHP Recommended for EU Approval for Previously Untreated DLBCL

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion in favor of the approval of polatuzumab vedotin for use in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone in patients with previously untreated diffuse large B-cell lymphoma. The European Medicines Agency’s Committee for…

Continue Reading Polatuzumab Vedotin Plus R-CHP Recommended for EU Approval for Previously Untreated DLBCL

Gopal Addresses Differences Between Real-World and Clinical Trial Data for DLBCL

During a Targeted Oncology case-based roundtable event, Ajay K. Gopal, MD, discussed the options for second-line and subsequent treatment of a patient with relapsed/refractory diffuse large B-cell lymphoma who refuses CAR T-cell therapy. Targeted OncologyTM: What are the recommended approaches for relapsed/refractory DLBCL in the second-line and subsequent therapies settings?…

Continue Reading Gopal Addresses Differences Between Real-World and Clinical Trial Data for DLBCL

Pacylex Pharmaceuticals Announces Publication in Current Oncology of First Clinical Experience with an N-myristoyltransferase (NMT) inhibitor in a Patient with Diffuse Large B-cell Lymphoma (DLBCL)

Edmonton, Alberta–(Newsfile Corp. – March 14, 2022) – Pacylex Pharmaceuticals, an oncology company developing a first-in-class, oral drug for a new approach to cancer therapy, today announced the publication in the journal Current Oncology of data from the first patient. The paper entitled “Novel, First-in-Human, Oral PCLX-001 Treatment in a…

Continue Reading Pacylex Pharmaceuticals Announces Publication in Current Oncology of First Clinical Experience with an N-myristoyltransferase (NMT) inhibitor in a Patient with Diffuse Large B-cell Lymphoma (DLBCL)

BTG2 gene predicts poor outcome in PT-DLBCL

Introduction Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare and aggressive form of mature B-cell lymphoma.1–3 PT-DLBCL was the most common type of testicular tumor in men aged over 60 and characterized by painless uni- or bilateral testicular masses with infrequent constitutional symptoms.4–6 PT-DLBCL shows significant extranodal tropism,…

Continue Reading BTG2 gene predicts poor outcome in PT-DLBCL

Top 17 b cell lymphoma treatment in 2022

Below are the best information and knowledge on the subject b cell lymphoma treatment compiled and compiled by our own team tuhoangkaido: 1. Treating B-Cell Non-Hodgkin Lymphoma 2. Treatments for B-Cell Lymphoma 3. Diffuse Large B-Cell Lymphoma: Treatment Options 4. B-cell Lymphoma 5. B-cell Lymphoma: Types, Symptoms & Prognosis 6….

Continue Reading Top 17 b cell lymphoma treatment in 2022

Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review

This article was originally published here J Int Med Res. 2022 Feb;50(2):3000605221081672. doi: 10.1177/03000605221081672. ABSTRACT Lung adenocarcinoma is one of the most common solid tumors, and diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of adult non-Hodgkin’s lymphoma. Although extra-nodular lesions are frequently observed in patients with…

Continue Reading Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review

EFFICACY AND SAFETY OF CYCLOPHOSPHAMIDE LOW-DOSE PRE-PHASE CHEMOTHERAPY IN DIFFUSE LARGE B CELL LYMPHOMA WITH GASTROINTESTINAL INVOLVEMENT

Luca Guarnera Hematology, Department of Biomedicine and Prevention, University Tor Vergara, Rome, Italy Federico Meconi Hematology, Department of Biomedicine and Prevention, University Tor Vergara, Rome, Italy Roberto Secchi Hematology, Department of Biomedicine and Prevention, University Tor Vergara, Rome, Italy Maria Rosaria Pascale Hematology, Department of Biomedicine and Prevention, University Tor…

Continue Reading EFFICACY AND SAFETY OF CYCLOPHOSPHAMIDE LOW-DOSE PRE-PHASE CHEMOTHERAPY IN DIFFUSE LARGE B CELL LYMPHOMA WITH GASTROINTESTINAL INVOLVEMENT

Polatuzumab Vedotin Plus R-CHOP May Improve Outcomes For DLBCL Patients

Thomas Habermann, MD, discusses R-CHOP and how it can be improved upon as a treatment method for diffuse large B-cell lymphoma. Thomas Habermann, MD, a hematologist with the Mayo Clinic, discusses the combination of rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as a treatment method for diffuse large B-cell…

Continue Reading Polatuzumab Vedotin Plus R-CHOP May Improve Outcomes For DLBCL Patients

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

1. Cancer biosimilar treatment trials have clinical outcomes that do not differ statistically from reference biologic products 2. The design elements of clinical trials for biosimilar drugs are rigorous Evidence Rating Level: 1 (Excellent) Study Rundown: Biologic treatments constitute a large portion of prescription costs in the United States. Biosimilar…

Continue Reading Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

Bristol Myers’ (BMY) Breyanzi sBLA Gets FDA’s Priority Review

This story originally appeared on Zacks Bristol-Myers Squibb Company BMY announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking approval for its CD19-directed CAR-T cell therapy, Breyanzi (lisocabtagene maraleucel), for an expanded use. – Zacks The sBLA seeks approval of Breyanzi…

Continue Reading Bristol Myers’ (BMY) Breyanzi sBLA Gets FDA’s Priority Review

Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma

February 16, 2022 3 min read Source/Disclosures Published by: Source: van Meerten T, et al. Abstract PT02-1. Presented at: European Society for Blood and Marrow Transplantation-European Hematology Association 4th European CAR T-cell Meeting (virtual meeting); Feb. 10-12, 2022. Disclosures: van Meerten reports honoraria from Kite Pharma and…

Continue Reading Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma

Estimating prediction accuracy of a Cox survival model using sbrier (R)

You can use the pec package, instead. Example: library(pec) set.seed(18713) library(prodlim) library(survival) dat=SimSurv(100) pmodel=coxph(Surv(time,status)~X1+X2,data=dat) perror=pec(list(Cox=pmodel),Hist(time,status)~1,data=dat) ## cumulative prediction error crps(perror) # between min time and 1 ## same thing: ibs(perror) library(survival) library(ipred) data(“DLBCL”, package = “ipred”) smod <- Surv(DLBCL$time, DLBCL$cens) coxmod <- coxph(smod ~ IPI, data = DLBCL) coxmod Call:…

Continue Reading Estimating prediction accuracy of a Cox survival model using sbrier (R)

Anti-CD19 CAR T-Cell Therapy for B-Cell Lymphoma

Researchers reported a favorable efficacy and manageable safety profile in anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for adults with B-cell lymphomas. Their data is presented in Frontiers in Genetics. Researchers, led by Wenyujing Zhou, aimed to determine the benefits and risks of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy…

Continue Reading Anti-CD19 CAR T-Cell Therapy for B-Cell Lymphoma

DLBCL : Lymphoma_MD_Answers

Hello Doctor (u/Erel_Joffe_MD) , DLBCL, non-germinal, Stage 1A lymphoma diagnosis. However, MRI indicates contiguous infiltration. Please help to advise on the current reported observation of MRI . “MRI indicates soft tissue lesion infiltrating into the right perivertebral region ( infiltrates the perivertebral muscles and abuts the lateral aspects) . vertebrae…

Continue Reading DLBCL : Lymphoma_MD_Answers

Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma, and hence, a comprehensive understanding based on the gene expression profile is imperative. Although several studies have identified some critical mutant genes of DLBCL, the disease in the central nervous system has not been investigated clearly….

Continue Reading Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database

Gilead’s CD47 clinical hold expands as CEO O’Day expresses ‘sense of urgency’ in getting trials back on track

Gilead revealed that a partial clinical hold for its CD47 targeted cancer hopeful is larger than originally thought. Last week, the California-based biotech shared that a handful of trials for magrolimab in combination with azacytidine had been placed on a partial clinical hold because of an “apparent imbalance” in adverse reactions…

Continue Reading Gilead’s CD47 clinical hold expands as CEO O’Day expresses ‘sense of urgency’ in getting trials back on track

Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma

doi: 10.1007/s12032-021-01642-3. Affiliations Expand Affiliations 1 Department of Blood Transfusion, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. 2 Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. 3 Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China. 4 Department of Blood Transfusion, Nanfang Hospital, Southern…

Continue Reading Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma

Paid research study for DLBCL patients and caregivers : lymphoma

I want to thank the community members who have already participated in this research and shared their insight and experiences. There are still spots available – please reach out or fill out the form below if you are interested. Help Us Better Understand Diffuse Large B-Cell Lymphoma (DLBCL) Pinpoint Patient…

Continue Reading Paid research study for DLBCL patients and caregivers : lymphoma

Clinical manifestations of diffuse large B-cell lymphoma that exhibits initial symptoms in the maxilla and mandible: a single-center retrospective study | BMC Oral Health

Table 1 summarizes the clinical findings at the initial examination. History of treatment before the initial examination Sixteen patients (59.3%) had previously undergone diagnosis and treatment of the site at a previous dental clinic or another Department of Oral Surgery prior to the initial examination at our department. Tooth extraction…

Continue Reading Clinical manifestations of diffuse large B-cell lymphoma that exhibits initial symptoms in the maxilla and mandible: a single-center retrospective study | BMC Oral Health

Front-Line Treatment of DLBCL – NewsBreak

Dr. Lenz on the Rationale for the CheckMate 9X8 in Metastatic CRC Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer. Heinz-Josef Lenz, MD, FACP, associate director, Clinical Research, J. Terrence Lanni Chair in Gastrointestinal Cancer Research, co-director, University of Southern…

Continue Reading Front-Line Treatment of DLBCL – NewsBreak

Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin’s lymphoma in the United States, with approximately 40% of first-line DLBCL chemoimmunotherapy attempts failing. The FDA approved a new type of antibody-drug conjugate (ADC), Zynlonta (loncastuximab tesirine), once called ADCT-402, on April 23, 2021, for relapsed or…

Continue Reading Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma

A Clinical and Immunohistochemical Study

Diffuse large B cell lymphoma is the most common type of lymphoma in Egypt with an unfavorable prognosis. The tumor microenvironment is rich in immune response either T cells or macrophages. The current study is aimed at testing CD4, CD8, CD68, and MMP9 immunohistochemistry of DLBCL activities with the prognosis…

Continue Reading A Clinical and Immunohistochemical Study

FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Officials with the FDA have granted both Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track Designation to C-CAR039, a novel autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients…

Continue Reading FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

Stream episode Is CAR-T Therapy Superior to ASCT for Relapsed/Refractory DLBCL? by Healthcare Unfiltered podcast

published on 2022-01-11T11:58:44Z Continuing his ASH Annual Meeting coverage, Chadi invites Matt Maurer (@MaurerStats), MS, principal biostatistician, Mayo Clinic, and Alan Skarbnik (@ASkarbnik), MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), to review the three prominent CAR-T studies in relapsed/refractory DLBCL presented at the meeting. Why…

Continue Reading Stream episode Is CAR-T Therapy Superior to ASCT for Relapsed/Refractory DLBCL? by Healthcare Unfiltered podcast

Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation

CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by poor prognosis after frontline immunochemotherapy. This retrospective study investigated the effect of consolidative radiation after systemic treatment in newly diagnosed stage I-II de novo CD5+ DLBCL. In this study, 22 patients received consolidative radiotherapy (RT) after immunochemotherapy (chemotherapy + RT…

Continue Reading Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation

Brem Looks at Multiple Treatments for Patients With DLBCL

During a Targeted OncologyTM Case-Based Roundtable event, Elizabeth A. Brem, MD, an assistant professor in Division of Hematology/Oncology, Department of Medicine at UC Irvine Health in Los Angeles, CA, moderated a discussion about a 43-year-old woman with diffuse large B-cell lymphoma. Targeted Oncology™: What therapeutic options would you consider at…

Continue Reading Brem Looks at Multiple Treatments for Patients With DLBCL

Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL

DISCUSSION QUESTIONS Do you foresee any barriers to using loncastuximab tesirine (Zynlonta) in diffuse large B-cell lymphoma (DLBCL)?​ If loncastuximab were covered by insurance, would you use it in the second line for patients who decline transplant?​ DEVA NATHAN, MD: I have different question. Are you willing to replace R-CHOP [rituximab…

Continue Reading Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL

Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

Introduction Rituximab (Rituxan; Genentech) is a chimeric anti-CD20 monoclonal antibody widely used in non-Hodgkin lymphoma (NHL) treatment.1 Worldwide, rituximab is recommended for a variety of B-cell malignancies,1,2 and it has a well-established efficacy and safety profile, with more than 4 million patients treated.1,3 In the United States, rituximab is approved…

Continue Reading Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

The Future of Targeted Therapies in DLBCL

In an interview with Targeted Oncology, Thomas Habermann, MD discusses the current unmet needs in the DLBCL space, along with the future of targeted therapies. While rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a highly effective therapy for diffuse large B-cell lymphoma (DLBCL). However, major unmet clinical needs still exist for patients with…

Continue Reading The Future of Targeted Therapies in DLBCL

MRD Surveillance in DLBCL – Capsule Summary Slidesets – Lymphomas and CLL – 2021 ASH Annual Meeting – Oncology

December 11-14, 2021; Atlanta, Georgia Results of this study showed that substantial proportions of clinical relapses were radiographically detected in asymptomatic patients, whereas immunosequencing MRD monitoring demonstrated suboptimal sensitivity. Format: Microsoft PowerPoint (.ppt) File Size: 484 KB Released: December 16, 2021 …

Continue Reading MRD Surveillance in DLBCL – Capsule Summary Slidesets – Lymphomas and CLL – 2021 ASH Annual Meeting – Oncology

MSK Chief of the Lymphoma Service Gilles Sall

December 14, 2021, NEW YORK, NY – A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) resulted in a…

Continue Reading MSK Chief of the Lymphoma Service Gilles Sall

Promising new treatment for patients with diffuse large B-cell lymphoma

Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0 A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin,…

Continue Reading Promising new treatment for patients with diffuse large B-cell lymphoma

Fate Therapeutics Highlights Positive Durability of

6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million FT516 Cells per Dose 3 of 8 Patients Previously Treated with Autologous CAR T-cell Therapy Achieve Complete Response…

Continue Reading Fate Therapeutics Highlights Positive Durability of

Should patients with DLBCL refractory to frontline RCHOP (or similar) or relapsing within

New data from ASH-2021 /NEJM ZUMA-7 trial (transformed FL were included in this study) Take home messages: Only 30% of patients who are treated with salvage chemotherapy will attain a complete response. Patients with a CR who proceed to ASCT do as well as patients on CAR-T upfront with good…

Continue Reading Should patients with DLBCL refractory to frontline RCHOP (or similar) or relapsing within

Real-World Study of Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Shows Efficacy, Safety

Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety. Real-world data on the use of tisagenlecleucel (Kymriah) showed greater efficacy and a favorable safety profile, according to updated findings from a study of the Center for…

Continue Reading Real-World Study of Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Shows Efficacy, Safety

Addition of Ibrutinib to R-Mini-Chop for Newly Diagnosed DLBCL Shows Promise in an Elderly Population

Adding ibrutinib (Imbruvica) to rituximab (Rituxan) plus mini-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone [R-mini-CHOP]) improved progression-free survival (PFS), quality of life (QOL), and function in elderly patients with diffuse large B-cell lymphoma (DLBCL), according to the primary analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study presented the 63rd…

Continue Reading Addition of Ibrutinib to R-Mini-Chop for Newly Diagnosed DLBCL Shows Promise in an Elderly Population

CAR-T therapy trials show promise for earlier use in lymphoma

Cell therapy, a relatively new and expensive treatment for certain blood cancers, might soon dislodge a decades-old standard of care for people with a common type of lymphoma that’s returned after initial drugs fail. Results from two late-stage studies, presented over the weekend at the American Society of Hematology’s annual…

Continue Reading CAR-T therapy trials show promise for earlier use in lymphoma

Vincerx Pharma Presents Data o

VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL webinar today, Saturday, December 11, 2021, at 7:30pm EST PALO ALTO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC) a biopharmaceutical company…

Continue Reading Vincerx Pharma Presents Data o

Ibrutinib Plus R-Mini-CHOP Misses OS End Point but Shows Improved PFS in Newly Diagnosed DLBCL

Ibrutinib plus rituximab and mini-CHOP failed to demonstrate a statistically significant improvement in overall survival at 2 years but led to an improvement in progression-free survival, quality of life, and function in elderly patients with diffuse large B-cell lymphoma. Ibrutinib (Imbruvica) plus rituximab (Rituxan) and mini-CHOP (cyclophosphamide, doxorubicin, vincristine, and…

Continue Reading Ibrutinib Plus R-Mini-CHOP Misses OS End Point but Shows Improved PFS in Newly Diagnosed DLBCL

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell non-Hodgkin lymphomas. Data will be…

Continue Reading Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL

Treatment with tafasitamab (Monjuvi) and lenalidomide (Revlimid) provided an overall survival (OS) benefit vs standard options in a population of patients with autologous stem cell transplant (ASCT)–ineligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to findings from an expanded analysis of RE-MIND2 study (NCT04697160) that was presented at the 2021…

Continue Reading Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL

Loncastuximab Tesirine Plus Ibrutinib on Relapsed DLBCL Trends Favorable to LOTIS-3 Interim Analysis

A preliminary review of the current phase 2 LOTIS-3 trial (NCT03684694) presented at the 2021 American Society of Hematology (ASH) Annual Meeting revealed promising efficacy and encouraging safety in the combination of ibrutinib (Imbruvica) and loncastuximab tesirine (Zynlonta ) in patients with relapsed/refractory (R/R) disseminated large B-cell lymphoma (DLBCL). These…

Continue Reading Loncastuximab Tesirine Plus Ibrutinib on Relapsed DLBCL Trends Favorable to LOTIS-3 Interim Analysis

DGAP-News: ???????MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL

​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL 11.12.2021 / 18:00 The issuer is solely responsible for the content of this announcement. MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of…

Continue Reading DGAP-News: ???????MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL

Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of results from a prespecified interim analysis of the pivotal TRANSFORM study, a global, randomized, multicenter, Phase 3 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, as a second-line treatment in…

Continue Reading Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Prof Brian Hill speaks to ecancer about a study he presented at the ASH 2021 meeting into potentially targetable pathways for CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL). He explains that the purpose of the study was to determine the impact of subtypes of DLBCL on the outcomes…

Continue Reading Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Liso-Cel Yields EFS Benefit as Second-line Therapy in LBCL

The phase 3 TRANSFORM study (NCT03575351) showed that patients with relapsed or refractory large B-cell lymphoma (LBCL) had a clinically meaningful improvement in event-free survival (EFS) compared with the standard of care (SOC) when treated with liscocabtagene maraleucel (liso-cel), according to prespecified interim results that were presented at the 2021…

Continue Reading Liso-Cel Yields EFS Benefit as Second-line Therapy in LBCL

Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab

(RTTNews) – MorphoSys AG (MOR) and Incyte (INCY) announced the additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma or DLBCL. The treatments include polatuzumab vedotin plus…

Continue Reading Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab

Loncastuximab Tesirine Plus Ibrutinib in Relapsed DLBCL Trends Favorably at LOTIS-3 Interim Analysis – NewsTVPK

An interim analysis of the ongoing phase 2 LOTIS-3 trial (NCT03684694), which was presented at the 2021 Annual Meeting of the American Society of Hematology (ASH), revealed promising efficacy and encouraging safety with the combination of ibrutinib (Imbruvica) plus loncastuximab thesis (Zynlonta) in patients with recurrent / resistant (R /…

Continue Reading Loncastuximab Tesirine Plus Ibrutinib in Relapsed DLBCL Trends Favorably at LOTIS-3 Interim Analysis – NewsTVPK

Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab Combination Data

(RTTNews) – MorphoSys AG (MOR) and Incyte (INCY) announced the additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma or DLBCL. The treatments include polatuzumab vedotin plus…

Continue Reading Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab Combination Data

Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

CAMBRIDGE, Mass., December 11, 2021–(BUSINESS WIRE)–Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today shared preclinical data and the Phase 1/1b trial design for EZM0414, the Company’s novel, first-in-class, oral SETD2 inhibitor, an investigational agent being developed for the…

Continue Reading Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL webinar today, Saturday, December 11, 2021, at 7:30pm EST PALO ALTO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC) a biopharmaceutical company…

Continue Reading Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The MarketWatch News Department was not involved in the creation of this content. December 11, 2021 (ACCESSWIRE via COMTEX) — – RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies – Results from the retrospective cohort analysis indicate significant overall survival improvement…

Continue Reading MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Liso-cel significantly improves outcomes in second-line DLBCL

December 11, 2021 2 min read Source/Disclosures Published by: Source: Kamdar M, et al. Abstract 91. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021. Disclosures: Kamdar reports consultant/advisory or speakers bureau roles with AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene, Genentech, Karyopharm…

Continue Reading Liso-cel significantly improves outcomes in second-line DLBCL

EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

December 11, 2021 3 min read Source/Disclosures Published by: Source: Locke FL, et al. Abstract 2. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021. Disclosures: Kite Pharma sponsored this study. Leslie reports advisory board, consultant or speakers bureau roles with AbbVie, AstraZeneca, BeiGene, Celgene/Bristol Myers…

Continue Reading EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

The combination of tafasitamab (Monjuvi) and lenalidomide (Revlimid) prolonged median overall survival (OS) compared with other standard options for autologous stem cell transplant (ASCT)-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a closely matched expanded analysis of the observational, retrospective RE-MIND2 (NCT04697160) study presented at the…

Continue Reading Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

Loncastuximab Tesirine/Ibrutinib Combination Elicits Encouraging Activity in Relapsed/Refractory DLBCL

Treatment with ibrutinib plus loncastuximab tesirine-lpyl resulted in high objective and complete response rates and an acceptable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma, according to findings from an interim analysis of the phase 1/2 LOTIS-3 trial (NCT03684694) that were presented at the 2021 ASH Annual Meeting…

Continue Reading Loncastuximab Tesirine/Ibrutinib Combination Elicits Encouraging Activity in Relapsed/Refractory DLBCL

Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma

1. Metser, U., Hussey, D. & Murphy, G. Impact of (18)F-FDG PET/CT on the staging and management of follicular lymphoma. Br. J. Radiol. 87, 20140360 (2014). CAS  Article  Google Scholar  2. Freedman, A. & Jacobsen, E. Follicular lymphoma: 2020 update on diagnosis and management. Am. J. Hematol. 95, 316–327 (2020)….

Continue Reading Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma

Double-hit lymphoma: optimizing therapy – Docwire News

This article was originally published here Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):157-163. doi: 10.1182/hematology.2021000247. ABSTRACT Aggressive B-cell lymphoma is a heterogeneous entity with disparate outcomes based on clinical and pathological characteristics. While most tumors in this category are diffuse large B-cell lymphoma (DLBCL), the recognition that some…

Continue Reading Double-hit lymphoma: optimizing therapy – Docwire News

Chugai Pharmaceutical : Files for Additional Indication of Polivy for Previously Untreated Diffuse Large B-cell Lymphoma

Chugai Files for Additional Indication of Polivy for Previously Untreated Diffuse Large B-cell Lymphoma Polivy plus R-CHP significantly improved outcomes in previously untreated diffuse large B-cell lymphoma (DLBCL) compared to the standard of care for the first time in 20 years Filing…

Continue Reading Chugai Pharmaceutical : Files for Additional Indication of Polivy for Previously Untreated Diffuse Large B-cell Lymphoma

Pola-G-Len Regimen Shows Promise as an Alternative to CAR T Cells in Refractory FL

The combination of obinutuzumab (Gazyva) with polatuzumab vedotin (Polivy) or lenalidomide (Revlimid; Pola-G-Len) achieved high responses in patients with heavily pretreated refractory follicular lymphoma (FL) in a phase 1b/2 clinical trial. “Our findings demonstrated that the regimen of Pola-G-Len was safe and had a high level of activity in relapsed…

Continue Reading Pola-G-Len Regimen Shows Promise as an Alternative to CAR T Cells in Refractory FL

Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test for Investigational Lymphoma Treatment

NEW YORK – Qiagen and Denovo Biopharma said on Thursday that they are collaborating to develop a blood-based companion diagnostic test to identify patients expressing a genomic biomarker who are likely to respond to Denovo’s investigational DB102 treatment for diffuse large B-cell lymphoma. Under the agreement, Qiagen will develop an…

Continue Reading Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test for Investigational Lymphoma Treatment

Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. QIAGEN (NYSE: QGEN) and Denovo Biopharma LLC today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) who…

Continue Reading Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

Circulating Exosomal MicroRNAs as Diagnostic and Prognostic Biomarkers in Patients with Diffuse Large B-Cell Lymphoma

Background: Exosomal microRNAs (miRNAs) are potential biomarkers for a variety of tumors but have not yet been studied in diffuse large B-cell lymphoma (DLBCL). Here, we investigated the use of exosomal miRNAs in DLBCL diagnosis and prognosis. Methods: A total of 256 individuals, including 133 DLBCL patients, 94 healthy controls…

Continue Reading Circulating Exosomal MicroRNAs as Diagnostic and Prognostic Biomarkers in Patients with Diffuse Large B-Cell Lymphoma

Part 1: Choosing a Third-Line Treatment for Refractory DLBCL

DISCUSSION QUESTION What are the key factors that influence your decision making for third-line therapy? PAOLO CAIMI, MD: What are the key factors that influence your decision in choice of regimen for patients who are in the third-line therapy? Any comments about the things that you use when you’re thinking…

Continue Reading Part 1: Choosing a Third-Line Treatment for Refractory DLBCL

MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1)

doi.org/10.1016/j.leukres.2021.106769Get rights and content Highlights • MiR-665 is down-regulated in the serum exosomes from DLBCL patients. • MiR-665 suppresses DLBCL cell proliferation and invasion and induces apoptosis. • LASP1 is a target of miR-665. • MiR-665 regulates DLBCL progression through targeting and inhibiting LASP1. Abstract Diffuse large B cell lymphoma…

Continue Reading MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1)

Qiagen, Denovo Biopharma Partner To Develop Companion Diagnostic Test

Published: 12/09/2021 06:38 GMT Qiagen NV (QGEN) – Qiagen and Denovo Biopharma Partner to Develop Companion Diagnostic Test for Treatment of Diffuse Large B-cell Lymphoma (dlbcl).Qiagen’s Blood-based Test Will Help to Identify Patients With Diffuse Large B-cell Lymphoma (dlbcl) Likely to Respond to Denovo’s New Investigational Cancer Treatment Db102tm.Partners Seek…

Continue Reading Qiagen, Denovo Biopharma Partner To Develop Companion Diagnostic Test

Qiagen, Denovo To Develop Companion Diagnostic Test For Diffuse Large B-Cell Lymphoma Treatment

(RTTNews) – Qiagen (QGEN) and Denovo Biopharma said that they have collaborated to develop a blood-based companion diagnostic test to identify patients expressing Denovo Genomic Marker 1 who are likely to respond to Denovo’s investigational cancer drug DB102 for treatment of diffuse large B-cell lymphoma or DLBCL, one of the…

Continue Reading Qiagen, Denovo To Develop Companion Diagnostic Test For Diffuse Large B-Cell Lymphoma Treatment

In some lymphomas, ibrutinib yields “almost unheard-of” survival rates

Younger patients with two genetic subtypes of diffuse large B cell lymphoma (DLBCL) – specifically MCD and N1 – show substantial improvements in survival with the addition of ibrutinib to standard R-CHOP chemotherapy, compared with R-CHOP alone, new research shows. The findings, published Nov. 4, 2021, in Cancer Cell, come…

Continue Reading In some lymphomas, ibrutinib yields “almost unheard-of” survival rates

MD Anderson research highlights 9 December

ATLANTA ― The University of Texas MD Anderson Cancer Center‘s Research Highlights provides a glimpse into basic, translational and clinical cancer research from MD Anderson experts. This special edition features presentations at the 2021 American Society of Hematology (ASH) Annual Meeting on innovative targeted therapies, new combination approaches, and novel…

Continue Reading MD Anderson research highlights 9 December